Roche Pharmaceutical Development and Sales Overview
Pharma Division CER sales growth¹ in %
Top 20 products by region
Roche
US
Europe
Q4 Q1 Q2
Q3
Q4
Q1
Q2 Q3
Q4
Japan
Q1 Q2 Q3
International
Q4 Q1 Q2
Q3
Ocrevus
Perjeta
Hemlibra
الله نه الله
12 10
17
26
34
34 11
51 29 62
26
-2
-1
4
이
-8
-21
-12
-15
-3 -1 -1
-1
24
32
37
30
33
28
24
16
53
31
29
36
30
Tecentriq
2
10
15
3
41
14
24
17
Actemra/RoActemra
67
22
-31
-61
18
-4
-2
-3
5
Herceptin
-34
-26
-29
-29
-3
-13
-9
-18
-36
36
-30
Avastin
-45
-39
-36
-31
-49
-56
-49 -47
55232
15 24 22
55
63
115
53
34 -5 -9
0
24
0
17
30
12 -2 -4
-55
-30
-44 -44
-27
-28
17
-18 -3 -22
0 -12 -13
-19
-24 -23 -17 -23
Xolair
14
9
13
8
I
I
-
I
I
MabThera
-32
-20
-24
-14
-13
-19
-16
-18
Kadcyla
3
0
-1
-8
16
8
12
3
Alecensa
18
25
14
TNKase/Activase
22
-21
1
26
22
9
5
8
5
25
-17 -15
42 28
7
1789
225
-13
-15 -23 -13 -32
16
38 26 81
4
25 45 29
12
46
9
-6
7 -3 4 12
Lucentis
2
-26 -9
-39
Evrysdi
112
36
28
13
*
227
216
*
*
-5 231
Ronapreve
-61
-99
-54
-100
-68
-99
Esbriet
-7
-4
-28
-67
0
-5
1
1
-36
-36 -36 109
Gazyva
11
0
3
7
2
-5
-8
-9
-7
-10 -17
* 87
75
101
91
*
Phesgo
236
187
134
62
188 107
I
1
278
20
Pulmozyme
6
0
5
2
-15
-11
-12
-12
CellCept
-31
-15
-17
-25
3
-7
-7
-5
29
22
-9
18
11 44 -1
45
-8 -9
13
-4 14 -16
-14
3
-29
CER = Constant Exchange Rates; * over 500%; 1 Q4/21 vs Q4/20; Q1-Q3/22 vs Q1-Q3/21
149View entire presentation